CALCIQUICK ALFA (Alfacalcidol (0.25mcg))

CALCIQUICK ALFA CAP is utilized for the prevention and treatment of deficiencies associated with vitamin D. It plays a crucial role in addressing complications arising from inadequate parathyroid function, ensuring that calcium levels remain stable in individuals undergoing dialysis due to chronic kidney failure. Furthermore, this medication is effective in managing renal osteodystrophy, a condition linked to bone deterioration in patients with kidney disorders. In addition to these uses, CALCIQUICK ALFA CAP aids in the treatment of elevated phosphate levels in the body, which can result from various metabolic issues. It is also indicated for the management and treatment of rickets, a disorder characterized by weakened bones, typically in children, caused by a deficiency in vitamin D, calcium, or phosphate. By facilitating the maintenance of appropriate mineral levels, CALCIQUICK ALFA CAP contributes to overall bone health and metabolic balance. Patients using this medication should be monitored regularly to ensure optimal efficacy and to manage any potential complications that may arise from its use. Always consult with a healthcare provider for personalized recommendations and guidance regarding this treatment. Use this medicine only under medical supervision. Follow the dose and schedule exactly as advised. Do not stop abruptly without guidance. Keep a record of any unusual symptoms and share them with your clinician. Combine therapy with appropriate lifestyle measures and routine monitoring as recommended.